Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) pathway is a key regulator of cell growth and survival, often dysregulated in cancer.
• mTOR activation contributes to cisplatin resistance in ovarian cancer.
• Cardamonin, a natural compound, exhibits anti-proliferative effects in cancer cells via mTOR inhibition.

Purpose of the Study:

• To investigate the synergistic anti-proliferative effects of combining cardamonin and cisplatin in ovarian cancer cells.
• To elucidate the underlying molecular mechanisms, including effects on the mTOR pathway and anti-apoptotic proteins.

Main Methods:

• Ovarian cancer cell proliferation was assessed using MTT assays.
• Cell cycle progression was analyzed.
• Western blot analysis was employed to evaluate mTOR signaling pathway activation and the expression of apoptosis-related proteins (Bcl-2, XIAP, Survivin).

Main Results:

• Cardamonin significantly potentiated the anti-proliferative and cell cycle arrest effects of cisplatin.
• Combination treatment led to a significant decrease in the expression of anti-apoptotic proteins: B cell lymphoma-2, X-linked inhibitor of apoptosis protein, and Survivin.
• Cardamonin effectively inhibited the activation of mTOR and its downstream target, 70 kDa ribosomal protein S6 kinase.

Conclusions:

• Cardamonin combined with cisplatin demonstrates enhanced anti-proliferative efficacy in ovarian cancer cells.
• The synergistic effect is mediated through the suppression of anti-apoptotic protein expression and inhibition of the mTOR signaling pathway.
• This combination therapy represents a potential strategy for overcoming cisplatin resistance in ovarian cancer.